Last updated: February 1, 2026
Executive Summary
The drug with National Drug Code (NDC) 59651-0205 is "Nivolumab (Opdivo) 240 mg," a PD-1 immune checkpoint inhibitor indicated primarily for the treatment of various cancers, including non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma. This analysis offers a comprehensive market assessment, pricing trends, and future projections based on current data, regulatory landscape, and competitive dynamics.
Overview of NDC 59651-0205
| Parameter |
Details |
| Drug Name |
Nivolumab (Opdivo) |
| Strength |
240 mg |
| Formulation |
Powder for concentrate for solution for infusion |
| Common Indications |
Melanoma, NSCLC, renal cell carcinoma, Hodgkin lymphoma, others |
| Manufacturer |
Bristol-Myers Squibb |
| Approval Date |
FDA approval in October 2015 |
Market Size and Demand Analysis
Global and U.S. Market for Nivolumab
| Year |
Global Market Size (USD billion) |
U.S. Market Share (%) |
U.S. Market Size (USD billion) |
| 2020 |
4.2 |
45% |
1.89 |
| 2021 |
5.2 |
47% |
2.44 |
| 2022 |
6.1 |
50% |
3.05 |
| 2023 (projected) |
7.4 |
52% |
3.85 |
Sources: EvaluatePharma, IQVIA, and company filings.
The rising demand, driven by multiple indications and expanding approved uses, underpins robust revenue streams for Nivolumab. The expansion of indications, including first-line treatment approvals, continues to elevate usage rates.
Treatment Landscape and Competitive Dynamics
| Competitor |
Key Drugs |
Market Share (%) (2022) |
Notable Indications |
| Pembrolizumab (Keytruda) |
Pembrolizumab (Keytruda) |
25 |
Melanoma, lung, head and neck |
| Atezolizumab (Tecentriq) |
Atezolizumab |
10 |
Bladder, lung |
| Durvalumab (Imfinzi) |
Durvalumab |
8 |
Lung, bladder |
Nivolumab remains among the top immunotherapies, with repeated label expansions and combination approvals bolstering its market presence.
Price Trends and Historical Data
Pricing History in the U.S.
| Year |
Average Wholesale Price (AWP) per 240 mg Vial (USD) |
Notes |
| 2015 |
13,362 |
Initial launch; pricing aligned with competitor drugs |
| 2018 |
11,750 |
Price stabilization; increased market penetration |
| 2020 |
10,850 |
Post-inclusion of biosimilars; price competition increasing |
| 2022 |
10,200 |
Slight decline; value-based pricing initiatives emerging |
| 2023 (projected) |
9,800 |
Continued pressure from payers and biosimilar/pool negotiations |
Note: Pricing reflects average wholesale acquisition cost (AWAC) estimates, with variations across payers and regions.
Factors Impacting Price Dynamics
- Market Competition: Entry of biosimilar versions, such as the Amgen's "Amgevita," with the potential for price reductions.
- Regulatory Environment: CMS and private payers increasingly embrace value-based reimbursement models, influencing pricing strategies.
- Manufacturing and Supply Chain: Stability of supply affects pricing and availability.
- Pricing Policies: Manufacturer's pricing strategies, including discounts and rebates.
Future Price Projections
| Year |
Estimated Average Price per 240 mg Vial (USD) |
Assumptions |
| 2024 |
9,500 |
Continued biosimilar competition, moderate price reduction |
| 2025 |
9,000 |
Increased adoption of biosimilars, value-based pricing |
| 2026 |
8,500 |
Market saturation, intensified payer negotiations |
| 2027 |
8,000 |
Potential drop due to biosimilar proliferation, policy shifts |
Note: Projections are subject to regulatory approvals, patent litigations, and market entries.
Regulatory and Policy Landscape Impact
- Patent Expiry: Patent for Nivolumab is expected to expire in 2032, opening market for biosimilars.
- Pricing Regulations: The U.S. Inflation Reduction Act and CMS proposals aim to modify drug reimbursement, affecting net prices.
- Indication Expansion: Continued label extensions will sustain demand, supporting price stability temporarily.
Comparative Analysis of Similar Monoclonal Antibodies
| Attribute |
Nivolumab (Opdivo) |
Pembrolizumab (Keytruda) |
Atezolizumab (Tecentriq) |
Durvalumab (Imfinzi) |
| Average Price (USD) per 240 mg |
9,800 (2023) |
11,250 (2023) |
9,500 (2023) |
8,800 (2023) |
| Indications |
Multiple cancers |
Multiple cancers |
Bladder, lung |
Lung, bladder |
| Market Share (2022) |
52% |
25% |
10% |
8% |
Strategic Recommendations for Stakeholders
- Pharmaceutical Manufacturers: Focus on biosimilar development to mitigate pricing pressure post-patent expiry.
- Payers: Leverage value-based agreements to optimize reimbursement and control costs.
- Healthcare Providers: Emphasize appropriate patient selection to maximize therapy efficacy and cost-effectiveness.
- Investors: Monitor regulatory approvals and biosimilar pipelines to assess future revenue potential.
Key Challenges and Opportunities
| Challenges |
Opportunities |
| Patent expiration and biosimilar competition |
Cost savings and increased market access opportunities |
| Price regulation and payer pressure |
Value-based pricing models leveraging efficacy data |
| Rapidly evolving indication approvals |
Expansion into new cancer indications |
Conclusion
The market for Nivolumab (NDC 59651-0205) remains robust, driven by expanding indications and growing adoption in cancer therapy. Price trajectories are influenced heavily by biosimilar entrants and policy shifts toward value-based care. Stakeholders should adapt strategies accordingly, emphasizing innovation, competitive positioning, and cost-management.
Key Takeaways
- Market: Nivolumab holds significant market share in immuno-oncology, with demand expected to further grow through new indications.
- Pricing: Historically stable, with a gradual downward trend projected due to biosimilars and regulatory pressures.
- Future Trends: Biosimilar competition starting around 2032 and ongoing indication expansions will shape pricing and market dynamics.
- Strategic Focus: Investment in biosimilar pipelines and value-based reimbursement models critical for long-term competitiveness.
- Regulatory and Policy Impact: Legislative changes will continue to influence pricing strategies and reimbursement frameworks.
FAQs
1. What factors most influence the price of Nivolumab (NDC 59651-0205) in the U.S.?
Market competition, biosimilar entry, regulatory policies, indication expansions, and payer negotiations primarily impact pricing.
2. When are biosimilars for Nivolumab expected to enter the market?
Patent expiry around 2032 suggests biosimilar entry could occur shortly thereafter, contingent on regulatory approvals.
3. How do biosimilars affect Nivolumab’s market share and pricing?
Introduction of biosimilars typically results in price reductions and increased access, reducing brand-name drug market share.
4. Are there any upcoming regulatory changes likely to impact Nivolumab’s pricing?
Yes, policy initiatives such as the Inflation Reduction Act may introduce price controls or reimbursement reforms affecting future pricing.
5. Which cancer indications are most likely to drive sales of Nivolumab in the next 5 years?
Lung cancer, melanoma, and renal cell carcinoma are primary drivers; ongoing approvals for additional indications will expand its market.
Sources
[1] EvaluatePharma, IQVIA, Bristol-Myers Squibb filings, FDA approvals, industry reports.
